Advanced Wound Care

Our advanced wound care products are designed
for the management and treatment
of chronic and acute wounds.

Our advanced wound care products are designed for the management and treatment of of chronic and acute wounds.

We offer a comprehensive portfolio of regenerative medicine products, capable of supporting patients from early in the wound healing process through to wound closure, regardless of wound type.

Understanding wounds can be complicated, but we're committed to making it accessible.

Learn more about wounds ›

Regenerative medicine is a multidisciplinary field involving biology, medicine, and engineering. You can learn more about Organogenesis' approach.

Learn more about our approach ›
Advanced Wound Care Solutions
PuraPly®AM
PuraPly® Antimicrobial (PuraPly® AM) Wound Matrix is an FDA 510(k)-cleared Class II medical device indicated for the management of a variety of acute and chronic wound types, including partial and full-thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, trauma wounds, draining wounds, and first- and second-degree burns.1

PuraPly AM is an antimicrobial barrier consisting of a native, cross-linked ECM coated polyhexamethylene biguanide, or PHMB, a broad spectrum antimicrobial. It is this combination of native, cross-linked ECM and PHMB that manages bioburden and helps control the reformation of biofilm while supporting healing across a wide variety of wound types, regardless of severity or duration.2,3,4

PuraPly AM is supplied dry in sheet form. The device is packaged in sterile, sealed single pouches.1

Source:
  1. PuraPly antimicrobial [package insert]. Canton, MA: Organogenesis, Inc; 2015
  2. Hübner NO, Kramer A. Skin Pharmacol Physiol. 2010;23(suppl):17-27
  3. Negron L et al. Int Wound J. 2014;11:392-397.
  4. Wolcott RD et al. J Wound Care. 2010;19(8):320-328.
Learn more
PuraPly®
PuraPly® is an FDA 510(k)-cleared Class II medical device that is indicated for the management of wounds including: partial and full-thickness wounds, venous, diabetic, chronic vascular, and pressure ulcers, tunneled/undermined, surgical, trauma, and draining wounds. PuraPly consists of a fenestrated single-layer sheet of purified native ECM (Extra-cellular Matrix) intended for the management of wounds. It is supplied dry in sheet form and packaged in sterile, sealed single pouches.1

Source:
  1. PuraPly [package insert]. Canton, MA: Organogenesis, Inc; 2015.
Learn more
NuShield®
NuShield® is a more complete dehydrated placental allograft designed to protect and support healing in a variety of wound sizes and types. It is an easy-to-use, off-the-shelf product available in multiple sizes.1

Source:
  1. Data on File. Organogenesis Inc.
Learn more
Affinity®
Affinity® is the only fresh amniotic membrane that contains:1,2,3,4
  • viable cells (including Mesenchymal stem cells, fibroblasts, and epithelial cells)
  • angiogenic, regenerative and anti-inflammatory growth factors and cytokines
  • a native extracellular matrix and multiple important ECM proteins
Affinity is the only fresh, hypothermically stored amniotic membrane (not dehydrated; not frozen) used to address a variety of wound sizes and types.1,5

Source:
  1. Data on File. Organogenesis Inc. DR-0006
  2. McQuilling JP et al. Int Wound J. 2017;14(6):993-1005.
  3. Niknejad H et al. Eur Cells Materials. 2008;15:88-99.
  4. Ghatak S et al. Int J Cell Biol. 2015;834893.
  5. Affinity Instructions for Use, 2017.
Learn more
Apligraf®
Apligraf® is an FDA-approved, bioengineered living cell therapy indicated for the healing of venous leg ulcers (VLUs) and diabetic foot ulcers (DFUs).1

Source:
  1. Apligraf [package insert]. Canton, MA: Organogenesis Inc.; 2017.
Learn more
Novachor™
Novachor is the only fresh chorion membrane wound covering on the market - making it the closest to native, unprocessed chorionic tissue.

Novachor retains native tissue components including the following:
  • Viable cells1-3
  • Native ECM structure2-4
  • Growth factors/cytokines2-5
Please refer to the Novachor Package Insert for complete prescribing information.

Source:
  1. Data on file. DR-0008. Organogenesis Inc.
  2. McQuilling JP, et al. Int Wound J. 2017;14(6):993-1005.
  3. Niknejad H, et al. Eur Cells Mater. 2008;15:88-99.
  4. Mamede AC, et al. Cell Tissue Res. 2012;349(2):447-458.
  5. Data on File. Nov_DR-0003 Organogenesis Inc.
Learn more

Contact us for more information about Advanced Wound Care products

All fields required unless marked optional

We're sorry, it looks like something isn't right. Please see below.

THANK YOU

Your information has been received.

Learn more about Advanced Wound Care

Learn More

Learn more about Reimbursement

Visit Reimbursement